Susan B. Stewart - 11 Apr 2022 Form 4 Insider Report for Candel Therapeutics, Inc. (CADL)

Reporting relationship: Chief Regulatory Officer
Issuer ticker: CADL
Reported as of: 11 Apr 2022
Net transaction value: $0
SEC form: 4
Accepted by SEC: 12 Apr 2022, 17:15:10 UTC
Prior SEC filing: 26 Jul 2021
Source filing: View source filing
Reporting owner signature: /s/ John Canepa, as Attorney-In-Fact for Susan B. Stewart

Key filing fact

Susan B. Stewart filed Form 4 for Candel Therapeutics, Inc. (CADL) on 12 Apr 2022.

Key facts

This page summarizes Susan B. Stewart's Form 4 filing for Candel Therapeutics, Inc. (CADL).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 12 Apr 2022, 17:15.

Change

Previous filing in this sequence was filed on 26 Jul 2021.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

CADL transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value: $0
Shares: +20,000
Change %
Price: $0.000000
Shares after: 20,000
Date: 11 Apr 2022
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 20,000
Exercise price: $5.12
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

The shares underlying this option shall vest and become exercisable in forty-eight (48) equal monthly installments, with the first installment vesting on May 11, 2022, subject to the Reporting Person's continued service on each such vesting date.